Omadacycline for Acute Bacterial Skin and Skin-Structure Infections

Treatment for acute bacterial skin and skin-structure infections is becoming more challenging as organisms with antimicrobial resistance become more prevalent. In this randomized trial involving 655 adults with bacterial skin and skin-structure infections, omadacycline was noninferior to linezolid r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-02, Vol.380 (6), p.528-538
Hauptverfasser:	O’Riordan, William, Green, Sinikka, Overcash, J. Scott, Puljiz, Ivan, Metallidis, Symeon, Gardovskis, J, Garrity-Ryan, Lynne, Das, Anita F, Tzanis, Evan, Eckburg, Paul B, Manley, Amy, Villano, Stephen A, Steenbergen, Judith N, Loh, Evan
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Antibiotic resistance Antibiotics Bacteria Clinical trials Double-Blind Method Drug Administration Schedule Drug dosages Drug resistance Drug Resistance, Bacterial Female Gram-positive bacteria Humans Infusions, Intravenous Intention to Treat Analysis Linezolid Linezolid - adverse effects Linezolid - therapeutic use Male Methicillin Methicillin-Resistant Staphylococcus aureus - drug effects Middle Aged Morbidity Patients Pharmaceuticals Skin Skin Diseases, Bacterial - drug therapy Skin Diseases, Bacterial - microbiology Staphylococcus infections Statistical analysis Substance abuse treatment Survival Tetracyclines - adverse effects Tetracyclines - therapeutic use Ulcers Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Treatment for acute bacterial skin and skin-structure infections is becoming more challenging as organisms with antimicrobial resistance become more prevalent. In this randomized trial involving 655 adults with bacterial skin and skin-structure infections, omadacycline was noninferior to linezolid regardless of the causative pathogen, including MRSA.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1800170